肿瘤细胞治疗研究
英文原题：Engineered cells as glioblastoma therapeutics.
尽管近年来我们在胶质母细胞瘤遗传学和细胞生物学认识方面取得了显著进展，但迄今为止这并未带来该肿瘤治疗的改善。
尽管近期对胶质母细胞瘤遗传学和细胞生物学的认识显著进步，迄今尚未转化为更有效的治疗。除小分子、抗体和工程化病毒策略外，工程化细胞也正在作为胶质母细胞瘤疗法接受研究，包括 CAR-T、CAR-NK，以及工程化神经干细胞和间充质干细胞。本文综述该领域现状，首先讨论临床试验研究；这些研究已证明工程化细胞疗法用于胶质母细胞瘤具有可行性和安全性，并显示出一定活性。随后回顾临床前研究文献，比较不同起始细胞类型用于工程化细胞疗法的优缺点。最后讨论这一新兴但前景可期的胶质母细胞瘤治疗方式未来的发展方向。
In spite of significant recent advances in our understanding of the genetics and cell biology of glioblastoma, to date, this has not led to improved treatments for this cancer. In addition to small molecule, antibody, and engineered virus approaches, engineered cells are also being explored as glioblastoma therapeutics. This includes CAR-T cells, CAR-NK cells, as well as engineered neural stem cells and mesenchymal stem cells. Here we review the state of this field, starting with clinical trial studies. These have established the feasibility and safety of engineered cell therapies for glioblastoma and show some evidence for activity. Next, we review the preclinical literature and compare the strengths and weaknesses of various starting cell types for engineered cell therapies. Finally, we discuss future directions for this nascent but promising modality for glioblastoma therapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。
